Affordable Access

deepdyve-link
Publisher Website

Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases.

Authors
  • Hata, Katsura1
  • 1 Global Health Research Section, hhc Data Creation Center, Eisai Co., Ltd., 1-3, Tokodai 5-chome, Tsukuba-shi, Ibaraki 300-2635, Japan. Electronic address: [email protected] , (Japan)
Type
Published Article
Journal
Parasitology international
Publication Date
Dec 25, 2020
Volume
81
Pages
102278–102278
Identifiers
DOI: 10.1016/j.parint.2020.102278
PMID: 33370607
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Neglected tropical diseases (NTDs) are communicable diseases that are uncommon in developed countries but epidemic in developing countries in tropical and subtropical regions of the world. One of the important contributions expected of pharmaceutical companies is the development and provision of drugs effective against NTDs. Eisai's efforts toward improving global health have resulted in a rich portfolio of assets addressing six infectious diseases: malaria, tuberculosis, Chagas disease, lymphatic filariasis, leishmaniasis, and mycetoma. As the most advanced project, Eisai has developed E1224 (fosravuconazole l-lysine ethanolate), which is available in both intravenous and oral formulations, and provides ravuconazole, an active form of fosravuconazole, with a long plasma half-life. The first clinical trials of E1224, for Chagas disease, have already been completed, led by the Drugs for Neglected Diseases initiative (DNDi). As a result, parasite clearance was observed with E1224 during the treatment phase, but parasite regrowth was observed after the end of drug administration, suggesting that the mechanism of action of E1224 on Trypanosoma cruzi is static rather than parasiticidal. On the other hand, a clinical trial for eumycetoma in collaboration with DNDi is ongoing supported by the Global Health Innovative Technology Fund, and is examining the efficacy of weekly treatment with E1224 versus the current standard of care, daily treatment with itraconazole. In this manner, Eisai will continue its drug-discovery research projects in collaboration with various PDPs and academia supported by funding agencies. Copyright © 2021 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times